However, low-dose CTK also gives rise to higher lymphocyte-infiltrating BC TME, including Treg, but the repletion of Treg cells abolished the antitumor effect of low-dose CTK to some extent (191), which was consistent with a murine experiment (192). The gene discussed is MATK; the disease is breast cancer.